Comparison Between Bilateral Infraorbital Block Versus Intranasal Bupivacaine in Transsphenoidal Pituitary Adenoma Resection
Primary Purpose
Intraoperative Hypertension
Status
Recruiting
Phase
Phase 3
Locations
Egypt
Study Type
Interventional
Intervention
infraorbital block
topical intranasal bupivacaine
Sponsored by
About this trial
This is an interventional treatment trial for Intraoperative Hypertension
Eligibility Criteria
Inclusion Criteria:
- ASA I, II or III
- patients scheduled to undergo endoscopic transsphenoidal approach to remove tumor under general anesthesia
Exclusion Criteria:
- Patient's refusal
- Allergy to local anesthetics.
- Preoperative cerebrospinal fluid leak.
- Preoperative cardiac arrythmias.
- Seizure disorders.
- Patients with severe endocrinal disorders that affecting the craniofacial morphology as acromegaly and cushinoid features.
Sites / Locations
- Kasr Alaini hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Group A
Group B
Arm Description
the patients will receive bilateral infraorbital block
the patients will receive topical intranasal application of bupivacaine
Outcomes
Primary Outcome Measures
Mean arterial blood pressure
Secondary Outcome Measures
Intraoperative need for magnesium sulphate
Intraoperative need for iv magnesium sulphate up to 3 mg to maintain blood pressure 20% below baseline
Intraoperative need for fentanyl
Intraoperative need for iv fentanyl blouses 0.5 μg/kg (maximum total dose 5 μg/kg for the entire procedure) if no response to magnesium sulphate
Intraoperative need for nitroglycerine
Intraoperative need for iv nitroglycerine infusion (5 - 100 mic/min iv) if no response to magnesium sulphate and fentanyl
Postoperative need of pethidine
Postoperative need of pethidine boluses 25 mg with max.100 mg
Postoperative pain assessed by Numeric pain score
Pain score will be assessed postoperatively (using the verbal Numeric Rating Scale [NRS] 0-100; 0 = Non ,100 = Worst imaginable pain)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05301634
Brief Title
Comparison Between Bilateral Infraorbital Block Versus Intranasal Bupivacaine in Transsphenoidal Pituitary Adenoma Resection
Official Title
Comparison Between Hemodynamic Effect of Bilateral Infraorbital Block Versus Intranasal Application of Bupivacaine in Patients Undergoing Transsphenoidal Pituitary Adenoma Resection.A Comparative Randomized Controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Recruiting
Study Start Date
April 2, 2022 (Actual)
Primary Completion Date
September 2022 (Anticipated)
Study Completion Date
October 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Cairo University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The study will evaluate the efficacy of bilateral infraorbital nerve block versus preoperative nasal packing with long-acting local anesthetic bupivacaine in term of maintaining hemodynamics intraoperative within 20% below baseline to achieve adequate hypotensive anesthesia and longer duration of postoperative analgesia up to 24 hours in patients undergoing transsphenoidal pituitary adenoma resection.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intraoperative Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
56 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Group A
Arm Type
Active Comparator
Arm Description
the patients will receive bilateral infraorbital block
Arm Title
Group B
Arm Type
Active Comparator
Arm Description
the patients will receive topical intranasal application of bupivacaine
Intervention Type
Procedure
Intervention Name(s)
infraorbital block
Intervention Description
the patients will receive bilateral infraorbital block
Intervention Type
Procedure
Intervention Name(s)
topical intranasal bupivacaine
Intervention Description
the patients will receive topical intranasal application of bupivacaine
Primary Outcome Measure Information:
Title
Mean arterial blood pressure
Time Frame
at the time of mucosal dissection
Secondary Outcome Measure Information:
Title
Intraoperative need for magnesium sulphate
Description
Intraoperative need for iv magnesium sulphate up to 3 mg to maintain blood pressure 20% below baseline
Time Frame
the entire duration of surgery
Title
Intraoperative need for fentanyl
Description
Intraoperative need for iv fentanyl blouses 0.5 μg/kg (maximum total dose 5 μg/kg for the entire procedure) if no response to magnesium sulphate
Time Frame
the entire duration of surgery
Title
Intraoperative need for nitroglycerine
Description
Intraoperative need for iv nitroglycerine infusion (5 - 100 mic/min iv) if no response to magnesium sulphate and fentanyl
Time Frame
the entire duration of surgery
Title
Postoperative need of pethidine
Description
Postoperative need of pethidine boluses 25 mg with max.100 mg
Time Frame
24 hours postoprative
Title
Postoperative pain assessed by Numeric pain score
Description
Pain score will be assessed postoperatively (using the verbal Numeric Rating Scale [NRS] 0-100; 0 = Non ,100 = Worst imaginable pain)
Time Frame
24 hours postoprative
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
ASA I, II or III
patients scheduled to undergo endoscopic transsphenoidal approach to remove tumor under general anesthesia
Exclusion Criteria:
Patient's refusal
Allergy to local anesthetics.
Preoperative cerebrospinal fluid leak.
Preoperative cardiac arrythmias.
Seizure disorders.
Patients with severe endocrinal disorders that affecting the craniofacial morphology as acromegaly and cushinoid features.
Facility Information:
Facility Name
Kasr Alaini hospital
City
Cairo
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
abdelkhalek m Samy
Phone
01025854248
Email
dr.abdo86@gmail.com
First Name & Middle Initial & Last Name & Degree
Eman M Mahmoud
First Name & Middle Initial & Last Name & Degree
Khaled EL Elshafei
First Name & Middle Initial & Last Name & Degree
Mohamed F Elmahdy
12. IPD Sharing Statement
Learn more about this trial
Comparison Between Bilateral Infraorbital Block Versus Intranasal Bupivacaine in Transsphenoidal Pituitary Adenoma Resection
We'll reach out to this number within 24 hrs